300298 三诺生物
已收盘 03-27 15:00:00
资讯
新帖
简况
股市必读：三诺生物（300298）3月27日董秘有最新回复
证券之星 · 05:14
股市必读：三诺生物（300298）3月27日董秘有最新回复
三诺生物：公司二代CGM产品暂未向美国FDA正式提交注册申请
证券之星 · 03-27 19:42
三诺生物：公司二代CGM产品暂未向美国FDA正式提交注册申请
股市必读：三诺生物（300298）3月26日董秘有最新回复
证券之星 · 03-27
股市必读：三诺生物（300298）3月26日董秘有最新回复
股市必读：三诺生物（300298）3月20日董秘有最新回复
证券之星 · 03-23
股市必读：三诺生物（300298）3月20日董秘有最新回复
三诺生物（300298）披露取得七项医疗器械注册证公告，3月20日股价下跌2.05%
证券之星 · 03-20
三诺生物（300298）披露取得七项医疗器械注册证公告，3月20日股价下跌2.05%
三诺生物：公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理
证券之星 · 03-17
三诺生物：公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理
三诺生物：公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请
证券之星 · 03-16
三诺生物：公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请
股市必读：三诺生物（300298）3月5日董秘有最新回复
证券之星 · 03-06
股市必读：三诺生物（300298）3月5日董秘有最新回复
三诺生物：2025年上半年血压计业务实现收入0.93亿元，同比增长50%
证券之星 · 03-04
三诺生物：2025年上半年血压计业务实现收入0.93亿元，同比增长50%
股市必读：三诺生物（300298）3月3日董秘有最新回复
证券之星 · 03-04
股市必读：三诺生物（300298）3月3日董秘有最新回复
三诺生物：2025年上半年海外营收9.97亿元
中金财经 · 02-28
三诺生物：2025年上半年海外营收9.97亿元
三诺生物：公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证
证券之星 · 02-27
三诺生物：公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证
三诺生物（300298）披露取得五项医疗器械注册证暨注册变更公告，2月26日股价下跌1.54%
证券之星 · 02-26
三诺生物（300298）披露取得五项医疗器械注册证暨注册变更公告，2月26日股价下跌1.54%
三诺生物（300298）披露股份回购结果暨股份变动公告，2月24日股价上涨0.22%
证券之星 · 02-24
三诺生物（300298）披露股份回购结果暨股份变动公告，2月24日股价上涨0.22%
三诺生物：统筹考虑是否在PWS精准可穿戴产品管线中进行布局
证券之星 · 02-24
三诺生物：统筹考虑是否在PWS精准可穿戴产品管线中进行布局
三诺生物：不向下修正“三诺转债”转股价格
证券之星 · 02-24
三诺生物：不向下修正“三诺转债”转股价格
三诺生物：持续探索和优化市值管理的方式与路径
证券之星 · 02-10
三诺生物：持续探索和优化市值管理的方式与路径
股市必读：三诺生物（300298）2月6日董秘有最新回复
证券之星 · 02-09
股市必读：三诺生物（300298）2月6日董秘有最新回复
三诺生物：三诺全球研发中心项目在有序建设中
证券之星 · 02-06
三诺生物：三诺全球研发中心项目在有序建设中
股市必读：三诺生物（300298）2月5日董秘有最新回复
证券之星 · 02-06
股市必读：三诺生物（300298）2月5日董秘有最新回复
暂无数据
公司概况
公司名称：
三诺生物传感股份有限公司
所属行业：
专用设备制造业
上市日期：
2012-03-19
主营业务：
三诺生物传感股份有限公司的主营业务是血糖监测系统的生产和销售。公司的主要产品是血糖监测系统、糖化血红蛋白检测系统、血脂检测系统、血压计。公司作为血糖监测领域领先企业，相继获得国内外权威机构的高度认可和荣誉。荣获“国家企业技术中心”、“国家工程研究中心”、“国家技术创新示范企业”、“国家知识产权优势企业”、“国家科技进步二等奖”和“国家绿色工厂”等资质。
发行价格：
29.00
{"stockData":{"symbol":"300298","market":"SZ","secType":"STK","nameCN":"三诺生物","latestPrice":15.74,"timestamp":1774595013000,"preClose":15.46,"halted":0,"volume":3943320,"delay":0,"changeRate":0.0181,"floatShares":451000000,"shares":560000000,"eps":0.5033,"marketStatus":"已收盘","change":0.28,"latestTime":"03-27 15:00:00","open":15.42,"high":15.79,"low":15.3,"amount":61477600,"amplitude":0.0317,"askPrice":15.75,"askSize":233,"bidPrice":15.74,"bidSize":1019,"shortable":0,"etf":0,"ttmEps":0.5033,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":5,"adr":0,"adjPreClose":15.46,"symbolType":"stock","openAndCloseTimeList":[[1774575000000,1774582200000],[1774587600000,1774594800000]],"highLimit":17.01,"lowLimit":13.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":560267306,"isCdr":false,"pbRate":2.71,"roa":"--","peRate":31.273594,"roe":"6.28%","epsLYR":0.589,"committee":-0.096228,"marketValue":8819000000,"turnoverRate":0.0087,"status":0,"floatMarketCap":7103000000},"requestUrl":"/m/hq/s/300298/tweets","defaultTab":"tweets","newsList":[{"id":"2623536874","title":"股市必读：三诺生物（300298）3月27日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2623536874","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623536874?lang=zh_cn&edition=full","pubTime":"2026-03-30 05:14","pubTimestamp":1774818855,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，三诺生物报收于15.74元，上涨1.81%，换手率0.87%，成交量3.94万手，成交额6147.76万元。关于变更回购股份用途并注销部分回购股份的公告三诺生物拟将2024年8月7日完成回购的3,421,500股股份用途由“用于员工持股计划或者股权激励”变更为“用于减少公司注册资本”，并注销该部分股份。注销后公司总股本将由560,267,306股减至556,845,806股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000001109.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0114","BK0102","BK0251"],"gpt_icon":0},{"id":"2622034825","title":"三诺生物：公司二代CGM产品暂未向美国FDA正式提交注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2622034825","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622034825?lang=zh_cn&edition=full","pubTime":"2026-03-27 19:42","pubTimestamp":1774611724,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物03月27日在投资者关系平台上答复投资者关心的问题。您所提及的公司二代 CGM 产品 FDA 受理相关信息及公告均不属实。且公司已在互动易平台多次明确回复：公司二代CGM产品暂未向美国 FDA 正式提交注册申请。公司所有法定信息请以在巨潮资讯网披露的公告为准，敬请广大投资者理性甄别非法定渠道的不实信息，注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700042929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300298","BK0102","BK0114"],"gpt_icon":0},{"id":"2622254898","title":"股市必读：三诺生物（300298）3月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2622254898","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622254898?lang=zh_cn&edition=full","pubTime":"2026-03-27 02:13","pubTimestamp":1774548789,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，三诺生物报收于15.46元，下跌1.4%，换手率0.73%，成交量3.28万手，成交额5122.46万元。董秘最新回复投资者： 请问你公司总经理有没有直播带货的想法啊？和投资者互动一下啊？感谢您的建议和关注！当日关注点来自交易信息汇总：3月26日主力资金净流出558.25万元，显示主力短期看空情绪明显。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700004053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0114","BK0251","BK0102"],"gpt_icon":0},{"id":"2621168746","title":"股市必读：三诺生物（300298）3月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2621168746","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621168746?lang=zh_cn&edition=full","pubTime":"2026-03-23 03:14","pubTimestamp":1774206853,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，三诺生物报收于16.22元，下跌2.05%，换手率0.87%，成交量3.92万手，成交额6428.06万元。董秘最新回复投资者： 你好！来自公司公告汇总：三诺生物获颁七项医疗器械注册证，涵盖血糖、尿酸、乳酸检测产品及糖尿病管理软件。公司公告汇总关于取得医疗器械注册证的公告三诺生物传感股份有限公司近日收到湖南省药品监督管理局颁发的七项《医疗器械注册证》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032300001289.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","300298","BK0251"],"gpt_icon":0},{"id":"2620173218","title":"三诺生物（300298）披露取得七项医疗器械注册证公告，3月20日股价下跌2.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620173218","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620173218?lang=zh_cn&edition=full","pubTime":"2026-03-20 22:30","pubTimestamp":1774017059,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，三诺生物报收于16.22元，较前一交易日下跌2.05%，最新总市值为90.88亿元。该股当日开盘16.61元，最高16.64元，最低16.22元，成交额达6428.06万元，换手率为0.87%。三诺生物传感股份有限公司近日收到湖南省药品监督管理局颁发的七项《医疗器械注册证》。其中，前六项为新获批的II类医疗器械注册证，产品包括血糖试条、血糖尿酸测试条和乳酸试条；第七项为糖尿病管理系统软件的延续注册。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032000043761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","09996","300298","BK1222","09997","BK0102","BK1583","BK0114","159883","BK1574","BK1100"],"gpt_icon":0},{"id":"2620427819","title":"三诺生物：公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427819","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620427819?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:52","pubTimestamp":1773751957,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物03月16日在投资者关系平台上答复投资者关心的问题。公司始终坚守全球领先的糖尿病数字管理专家的战略定位，目前公司自研的生物传感技术主要应用于糖尿病及相关慢性疾病的监测及管理，暂未涉及脑机接口应用。公司二代CGM产品暂未向美国FDA正式提交注册申请，目前正按计划推进相关注册筹备工作，后续如有重大进展，公司将严格按照监管要求及时履行信息披露义务。感谢您对公司的关注！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031700039711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300298","BK0251","BK0114"],"gpt_icon":0},{"id":"2619450924","title":"三诺生物：公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450924","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619450924?lang=zh_cn&edition=full","pubTime":"2026-03-16 19:39","pubTimestamp":1773661144,"startTime":"0","endTime":"0","summary":"公司二代 CGM 产品暂未向美国 FDA 正式提交注册申请，目前正按计划推进相关注册筹备工作。鉴于二代 CGM 尚未正式提交美国 FDA 注册申请，且 FDA 医疗器械注册审核流程受产品技术特点、审核反馈、资料补充进度等多重因素影响，评审周期及最终注册结果均存在较大不确定性。因此，公司暂无法预测产品获批时间，后续如有重大进展，公司将严格按照相关法律法规和监管要求，及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600030667.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","BK0114","300298","BK0251"],"gpt_icon":0},{"id":"2617520802","title":"股市必读：三诺生物（300298）3月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2617520802","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617520802?lang=zh_cn&edition=full","pubTime":"2026-03-06 02:12","pubTimestamp":1772734334,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，三诺生物报收于16.89元，上涨0.96%，换手率0.83%，成交量3.76万手，成交额6340.61万元。董秘最新回复投资者： 刘烈宏局长近期强调要“加快建设一批数据领域重点实验室”。请问在这两大国家级平台中，三诺分别承担了哪些具体任务？当日关注点来自交易信息汇总：3月5日主力资金净流入34.36万元，游资积极介入，散户资金呈净流出态势。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600001139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK0251","BK0102","BK0114"],"gpt_icon":0},{"id":"2616558553","title":"三诺生物：2025年上半年血压计业务实现收入0.93亿元，同比增长50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616558553","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616558553?lang=zh_cn&edition=full","pubTime":"2026-03-04 20:54","pubTimestamp":1772628861,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物03月03日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，商务部数据显示今年年货期间智能血压仪血糖仪销售额增长超60%，反映健康消费需求旺盛。查阅公司财报，2024年血压计业务实现收入1.23亿元，同比增长10.61%。公司 2025年上半年血压计业务实现收入0.93 亿元，同比增长 50%，整体保持稳健发展态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400038188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300298","BK0114","BK0102"],"gpt_icon":0},{"id":"2616037607","title":"股市必读：三诺生物（300298）3月3日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2616037607","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616037607?lang=zh_cn&edition=full","pubTime":"2026-03-04 03:54","pubTimestamp":1772567651,"startTime":"0","endTime":"0","summary":"截至2026年3月3日收盘，三诺生物报收于17.08元，下跌1.1%，换手率1.41%，成交量6.35万手，成交额1.09亿元。董秘最新回复投资者： 董秘您好，面对春节消费中智能健康设备需求旺盛的趋势，30家机构预测公司2026年归母净利润有望同比增长65.11%，主要受益于CGM放量和海外业务改善。当日关注点来自交易信息汇总：3月3日主力资金净流出134.85万元，散户资金净流入563.86万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400004960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","BK0251","300298"],"gpt_icon":0},{"id":"2614815070","title":"三诺生物：2025年上半年海外营收9.97亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614815070","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614815070?lang=zh_cn&edition=full","pubTime":"2026-02-28 17:41","pubTimestamp":1772271665,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月28日在投资者关系平台上答复投资者关心的问题。公司已构建全球化的销售体系，业务覆盖超过180个国家及地区，海外市场已成为公司收入的重要组成。2025年上半年，公司实现海外地区营业收入9.97亿元，海外收入占比达到44.06%。关于具体国家的销售情况，请以公司后续发布的定期报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260228/32034953.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300298"],"gpt_icon":0},{"id":"2614834441","title":"三诺生物：公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2614834441","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614834441?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:42","pubTimestamp":1772188936,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月27日在投资者关系平台上答复投资者关心的问题。公司第二代CGM已于2024年12月13日取得国内Ⅲ类医疗器械注册证，并在2025年开始在国内上市销售。目前正在积极推进全球多国的注册工作。公司已建成CGM半自动化和全自动化生产线，未来将根据CGM产品业务发展情况及销售需求对产量进行动态调整，以满足国内外市场需求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700033980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK1583","BK0102","BK1100","159883","BK0251","300298","09996","09997","BK1222","BK0114"],"gpt_icon":0},{"id":"2614693023","title":"三诺生物（300298）披露取得五项医疗器械注册证暨注册变更公告，2月26日股价下跌1.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614693023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614693023?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:45","pubTimestamp":1772117116,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘，三诺生物报收于17.91元，较前一交易日下跌1.54%，最新总市值为100.34亿元。该股当日开盘18.14元，最高18.41元，最低17.88元，成交额达1.39亿元，换手率为1.71%。近日，三诺生物传感股份有限公司获得湖南省药品监督管理局颁发的五项医疗器械注册证和一项医疗器械变更注册文件。上述注册证的取得丰富了公司检测产品线，提升了产品技术性能，有助于增强市场竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300298","BK1100","BK0251","159883","09996","BK1583","BK0102","BK0114","BK1222","BK1574","09997"],"gpt_icon":0},{"id":"2613169792","title":"三诺生物（300298）披露股份回购结果暨股份变动公告，2月24日股价上涨0.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613169792","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613169792?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:18","pubTimestamp":1771928339,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘，三诺生物报收于17.97元，较前一交易日上涨0.22%，最新总市值为100.68亿元。公司于近日披露《关于股份回购结果暨股份变动的公告》。公告显示，三诺生物传感股份有限公司于2025年2月20日审议通过回购公司部分股份方案，拟使用自有资金及专项贷款以集中竞价方式回购股份，用于员工持股计划、股权激励或转换可转债。已回购股份将存放于专用账户，36个月内用于指定用途，否则将注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400035844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300298","BK0114","BK0102"],"gpt_icon":0},{"id":"2613923737","title":"三诺生物：统筹考虑是否在PWS精准可穿戴产品管线中进行布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2613923737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613923737?lang=zh_cn&edition=full","pubTime":"2026-02-24 18:12","pubTimestamp":1771927928,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月24日在投资者关系平台上答复投资者关心的问题。从生理机制而言，尿酸波动没有血糖波动频繁，其水平变化更多反映的是人体代谢平衡状态，日内波动相对平缓，但这并不意味着持续监测没有价值。如果市场对动态尿酸监测存在真实且明确的需求，公司将结合相关技术成熟度，统筹考虑是否在PWS精准可穿戴产品管线中进行布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400034802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","BK0251","300298"],"gpt_icon":0},{"id":"2613962387","title":"三诺生物：不向下修正“三诺转债”转股价格","url":"https://stock-news.laohu8.com/highlight/detail?id=2613962387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613962387?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:00","pubTimestamp":1771923647,"startTime":"0","endTime":"0","summary":"结合公司的经营实际、市场环境、股价走势等多重因素，公司董事会决定不向下修正“三诺转债”转股价格，是基于对公司的长期发展潜力与内在价值的信心，切实维护全体股东和债权人的整体和长远利益，同时明确投资者预期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400031209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","300298","BK0102","BK0251"],"gpt_icon":0},{"id":"2610640466","title":"三诺生物：持续探索和优化市值管理的方式与路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2610640466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610640466?lang=zh_cn&edition=full","pubTime":"2026-02-10 20:51","pubTimestamp":1770727903,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月09日在投资者关系平台上答复投资者关心的问题。管理层通过增持、高价回购及拒绝下修转股价，清晰传达了认为股价严重低估的信心。针对您的建议，公司高度重视并认真听取各方意见，将在严格遵守信息披露规范的前提下，持续探索和优化市值管理的方式与路径，不断优化投资者沟通机制，综合评估并完善投资者回报机制，引导公司的市场价值与内在价值趋同。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021000036791.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","BK0102","300298","BK0251"],"gpt_icon":0},{"id":"2610577183","title":"股市必读：三诺生物（300298）2月6日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2610577183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610577183?lang=zh_cn&edition=full","pubTime":"2026-02-09 02:05","pubTimestamp":1770573913,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，三诺生物报收于18.23元，上涨0.22%，换手率1.21%，成交量5.48万手，成交额9985.28万元。随着项目建成，三诺生物的产品iCARE、iCGMS将逐步实现规模化生产，预计年产值达30亿元，税收贡献增加超2亿元。来自公司公告汇总：三诺转债回售申报期为2026年2月9日至2月13日，回售价格为100.274元/张，当前可转债收盘价高于回售价，回售存在亏损风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900000993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","300298","BK0102","BK0114"],"gpt_icon":0},{"id":"2609689615","title":"三诺生物：三诺全球研发中心项目在有序建设中","url":"https://stock-news.laohu8.com/highlight/detail?id=2609689615","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609689615?lang=zh_cn&edition=full","pubTime":"2026-02-06 16:09","pubTimestamp":1770365352,"startTime":"0","endTime":"0","summary":"证券之星消息，三诺生物02月06日在投资者关系平台上答复投资者关心的问题。三诺全球研发中心项目在有序建设中，公司将严格按照项目规划积极推进，后续进展请以公司官方渠道发布的信息为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600024835.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0114","300298","BK0102","BK0251"],"gpt_icon":0},{"id":"2609583248","title":"股市必读：三诺生物（300298）2月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2609583248","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609583248?lang=zh_cn&edition=full","pubTime":"2026-02-06 02:09","pubTimestamp":1770314952,"startTime":"0","endTime":"0","summary":"截至2026年2月5日收盘，三诺生物报收于18.19元，上涨0.28%，换手率1.21%，成交量5.47万手，成交额9924.95万元。来自公司公告汇总：三诺转债触发回售条款，回售申报期为2026年2月9日至2月13日，回售价格为100.274元/张，当前市价高于回售价，回售存在亏损风险。三诺转债因公司股票连续三十个交易日收盘价低于当期转股价格的70%，触发有条件回售条款。回售期间三诺转债暂停转股，持有人可自主选择是否回售，不具强制性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600001726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0102","300298","BK0114","BK0251"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774828993958,"stockEarnings":[{"period":"1week","weight":-0.0296},{"period":"1month","weight":-0.1347},{"period":"3month","weight":-0.0975},{"period":"6month","weight":-0.2181},{"period":"1year","weight":-0.3447},{"period":"ytd","weight":-0.0801}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0563},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.0224},{"period":"1year","weight":0.1601},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"三诺生物传感股份有限公司","boardCode":"AI0035","boardName":"专用设备制造业","stockholders":"24597人(较上一季度增加58.52%)","perCapita":"18347股","listingDate":"2012-03-19","address":"湖南省长沙市岳麓区高新技术产业开发区谷苑路265号","registeredCapital":"56026万元","survey":" 三诺生物传感股份有限公司的主营业务是血糖监测系统的生产和销售。公司的主要产品是血糖监测系统、糖化血红蛋白检测系统、血脂检测系统、血压计。公司作为血糖监测领域领先企业，相继获得国内外权威机构的高度认可和荣誉。荣获“国家企业技术中心”、“国家工程研究中心”、“国家技术创新示范企业”、“国家知识产权优势企业”、“国家科技进步二等奖”和“国家绿色工厂”等资质。","listedPrice":29},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"三诺生物(300298)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供三诺生物(300298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"三诺生物,300298,三诺生物股票,三诺生物股票老虎,三诺生物股票老虎国际,三诺生物行情,三诺生物股票行情,三诺生物股价,三诺生物股市,三诺生物股票价格,三诺生物股票交易,三诺生物股票购买,三诺生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"三诺生物(300298)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供三诺生物(300298)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}